Yeongnam University Medical Center Trials

Yeongnam University Medical Center	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Lee, Jung-Hee

TIRA-FIM, NCT04770142: First-in-Man Early Feasibility Study for Transcatheter HOCM Septal Ablation

Recruiting

N/A

RoW

TIRA catheter, CA10 and ohter 3 models

Tau Pnu Medical Co., Ltd.

Hypertrophic Obstructive Cardiomyopathy

04/26

08/26

DOSE, NCT05702060: Randomized Comparison of Radiation Exposure to Operators in Coronary Intervention Between Right Radial and Left DRA

Recruiting

N/A

1010

RoW

Radial Artery Puncture Method for Coronary Angiography and Intervention

Yonsei University, Myung In Pharm

Radiation Exposure

12/25

Cho, Young Min

NCT06493799: In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

Not yet recruiting

226

LAENNEC (Human Placenta Hydrolysate) IV, LAENNEC (Human Placenta Hydrolysate) SC

Green Cross Wellbeing

Chronic Liver Disease

12/25

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Active, not recruiting

1083

Canada, US, RoW

Simufilam, PTI-125, Placebo

Cassava Sciences, Inc., Premier Research Group plc

Alzheimer Disease

05/25

TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting

1000

Europe, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea

05/26

NCT05718375: Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

Recruiting

240

RoW

CU01-1001, Placebo

Curacle Co., Ltd.

Diabetic Nephropathies

09/24

NCT04932928: Patient-Driven Lifestyle Modification Using FreeStyle Libre in Type 2 Diabetes Patients

Recruiting

N/A

126

RoW

FreeStyle Libre, Education on lifestyle modification, Blood glucose meter

Seoul National University Hospital, Inje University, Kangbuk Samsung Hospital

Diabetes Mellitus, Type 2, Lifestyle Risk Reduction

09/22

03/23

PERFUSE RCT, NCT02208388: Prospective Evaluation of MyocaRdial PerFUSion ComputEd Tomography Trial

Recruiting

N/A

1000

RoW

computed tomography perfusion guided treatment, Fractional flow reserve guided treatment

Young-Hak Kim, MD, PhD

Coronary Disease

03/28

Shin, Dong-Gu

NCT03932604: Atrial Sensing Capability for Better Detection of Atrial Fibrillation

Recruiting

N/A

640

RoW

Atrial sensing On mode

Samsung Medical Center, Biotronik SE & Co. KG

Implantable Cardioverter Defibrillator, Atrial Fibrillation, Cardiac Event, Cardiac Arrhythmia

12/21

05/23

KOH

MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting

1594

Europe, Canada, US, RoW

Teclistamab, JNJ-64007957, Lenalidomide

Stichting European Myeloma Network, Janssen Pharmaceutica

Multiple Myeloma

04/28

04/32

JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL

Completed

171

US, RoW

AZD4205

Dizal Pharmaceuticals

Relapsed or Refractory Peripheral T Cell Lymphoma

10/23

02/24

WON, KYUCHANG

NCT03403556: High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes

Recruiting

140

RoW

Rosuvamibe, Monorova

Yuhan Corporation

Atherosclerotic Cardiovascular Disease, Type 2 Diabetes

10/21

12/21

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting

1500

Europe, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight, Type 2 Diabetes

08/25

NCT05718375: Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

Recruiting

240

RoW

CU01-1001, Placebo

Curacle Co., Ltd.

Diabetic Nephropathies

09/24

Hong, Jun Hyuk

NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting

496

Europe, US, RoW

Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone

Jiangsu HengRui Medicine Co., Ltd.

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

12/26

NCT05718375: Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

Recruiting

240

RoW

CU01-1001, Placebo

Curacle Co., Ltd.

Diabetic Nephropathies

09/24

NCT06712615: Phase II Study of PG-102(MG12) Compared with Placebo in Obesity and Type 2 Diabetes

Recruiting

144

RoW

PG-102, Placebo

ProGen. Co., Ltd.

Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus

03/25

06/25

NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Active, not recruiting

145

Europe, Canada, Japan, US, RoW

GSK3858279, Placebo

GlaxoSmithKline

Pain

10/24

01/25

SOLUTION-2, NCT06374667: The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction

Recruiting

N/A

134

RoW

Y-3 ICO injection, Y-3 intravenous injection, Conventional treatment

yilong Wang

Stroke, Acute Ischemic, Blood-Brain Barrier

03/26

03/27

NCT05715138: Comparison of Pallidal With Subthalamic Deep Brain Stimulation for Cervical Dystonia

Not yet recruiting

N/A

RoW

GPi-DBS, STN-DBS, GPi-DBS devices, STN-DBS devices

Chinese PLA General Hospital

Cervical Dystonia

12/24

11/26

NCT05968248: Efficacy and Safety of Deep Brain Stimulation in Mesencephalic Locomotor Region（MLR） for Poststroke Hemiplegia

Not yet recruiting

N/A

MLR-DBS, Conventional rehabilitation group

Chinese PLA General Hospital

Stroke Sequelae

12/25

11/27

Won, Kyu-Chang

REMBRANDT, NCT04700436: Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia

Recruiting

240

RoW

Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg), Suvast tablet 10 mg (Rosuvastatin 10 mg)

Seoul National University Hospital, Gangnam Severance Hospital

Endocrine System Diseases, Nutritional and Metabolic Diseases, Diabetes Mellitus, Type 2, Dyslipidemias

05/21

11/21

Yoo, HyeJin

NCT05718375: Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

Recruiting

240

RoW

CU01-1001, Placebo

Curacle Co., Ltd.

Diabetic Nephropathies

09/24



	Diseases Companies Products Productz Mechanisms of Action Sites